blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3917912

EP3917912 - AMIDE-DISUBSTITUTED PYRIDINE OR PYRIDAZINE COMPOUNDS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  23.09.2022
Database last updated on 14.06.2024
FormerRequest for examination was made
Status updated on  05.11.2021
FormerThe international publication has been made
Status updated on  08.08.2020
Formerunknown
Status updated on  20.03.2020
Most recent event   Tooltip15.12.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2021/49]
Inventor(s)01 / SHERWOOD, Trevor C.
c/o Bristol-Myers Squibb Company,
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
02 / YANG, Michael G.
c/o Bristol-Myers Squibb Company,
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
03 / GILMORE, John L.
c/o Bristol-Myers Squibb Company,
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
04 / ZHANG, Yanlei
37 Kennedy Ct
Princeton, New Jersey 08540 / US
05 / XIAO, Zili
c/o Bristol-Myers Squibb Company,
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
06 / LIU, Qingjie
c/o Bristol-Myers Squibb Company,
Route 206 and Province Line Road
Princeton, New Jersey 08543 / US
[N/P]
Former [2021/49]01 / SHERWOOD, Trevor C.
Princeton, New Jersey 08543 / US
02 / YANG, Michael G.
Princeton, New Jersey 08543 / US
03 / GILMORE, John L.
Princeton, New Jersey 08543 / US
04 / ZHANG, Yanlei
Princeton, New Jersey 08540 / US
05 / XIAO, Zili
Princeton, New Jersey 08543 / US
06 / LIU, Qingjie
Princeton, New Jersey 08543 / US
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2021/49]
Application number, filing date20710338.328.01.2020
[2021/49]
WO2020US15291
Priority number, dateUS201962798566P30.01.2019         Original published format: US 201962798566 P
[2021/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020159904
Date:06.08.2020
Language:EN
[2020/32]
Type: A1 Application with search report 
No.:EP3917912
Date:08.12.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 06.08.2020 takes the place of the publication of the European patent application.
[2021/49]
Search report(s)International search report - published on:EP06.08.2020
ClassificationIPC:C07D213/82, C07D237/24, C07D401/12, C07D403/12, C07D405/14, C07D417/14, C07D413/12, C07B59/00, A61K31/44, A61K31/50, A61K31/501
[2021/49]
CPC:
C07D401/12 (EP,IL,KR,US); C07D403/12 (EP,IL,KR,US); A61K31/44 (KR);
A61K31/50 (KR); A61K31/501 (KR); A61K45/06 (EP,IL);
A61P29/00 (KR); A61P37/00 (KR); C07B59/002 (EP,IL);
C07D213/82 (EP,IL,KR,US); C07D237/24 (EP,IL,KR,US); C07D401/14 (KR,US);
C07D405/14 (EP,IL,KR,US); C07D413/12 (EP,IL,KR,US); C07D413/14 (KR,US);
C07D417/12 (KR,US); C07D417/14 (EP,IL,KR,US); C07B2200/05 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/49]
TitleGerman:AMID-DISUBSTITUIERTE PYRIDIN- ODER PYRIDAZIN-VERBINDUNGEN[2021/49]
English:AMIDE-DISUBSTITUTED PYRIDINE OR PYRIDAZINE COMPOUNDS[2021/49]
French:COMPOSÉS DE PYRIDINE OU DE PYRIDAZINE À DISUBSTITUTION AMIDE[2021/49]
Entry into regional phase27.08.2021National basic fee paid 
27.08.2021Designation fee(s) paid 
27.08.2021Examination fee paid 
Examination procedure27.08.2021Examination requested  [2021/49]
27.08.2021Date on which the examining division has become responsible
19.04.2022Amendment by applicant (claims and/or description)
26.09.2022Despatch of a communication from the examining division (Time limit: M04)
02.02.2023Reply to a communication from the examining division
27.06.2023Despatch of a communication from the examining division (Time limit: M04)
17.10.2023Reply to a communication from the examining division
Fees paidRenewal fee
20.12.2021Renewal fee patent year 03
14.12.2022Renewal fee patent year 04
14.12.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2014074661  (BRISTOL MYERS SQUIBB CO [US]) [X] 1-8,10-12 * Examples 12, 17, 28, 52-54, 63, 64, 69, 70, 72, 75, 78, 82, 90, 95, 101, 105, 116, 125, 126, 136, 138, 139, 141, 143, 146, 149, 159, 160, 162, 173, 174, 175, 176, 179, 181, 182, 184-190, 192, 194, 195, 196, 200, 201; page 21, paragraph 0049 - page 23, paragraph 0054; claims 1-4, 6-15 *;
 [X]WO2015069310  (BRISTOL MYERS SQUIBB CO [US]) [X] 1-7,9-12 * Examples 1-22, 25, 26, 28-46; page 15, paragraph 0042 - page 17, paragraph 0048; claims 1-8 *;
 [A]WO2018071794  (NIMBUS LAKSHMI INC [US]) [A] 1-12* claims 1-57 *
by applicant   - MCGEACHY, M.J. et al., "The link between IL-23 and Tht 7 cell-mediated immune pathologies", Semin. Immunol, (20070000), vol. 19, doi:10.1016/j.smim.2007.10.012, pages 372 - 376, XP022495318

DOI:   http://dx.doi.org/10.1016/j.smim.2007.10.012
    - GRACIE, J.A. et al., "Interleukin 12 induces interferon-gamma-dependent switching of IgG alloantibody subclass", Eur. J. Immunol., (19960000), vol. 26, pages 1217 - 1221
    - SCHRODER, K. et al., "Interferon-gamma: an overview of signals, mechanisms and functions", J. Leukoc. Biol., (20040000), vol. 75, no. 2, doi:10.1189/jlb.0603252, pages 163 - 189, XP009031305

DOI:   http://dx.doi.org/10.1189/jlb.0603252
    - KYTTARIS. V.C. et al., "Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-Ipr/Ipr mice", J. Immunol, (20100000), vol. 184, pages 4605 - 4609
    - HONG, K. et al., "IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis like skin disorder", J. Immunol, (19990000), vol. 162, pages 7480 - 7491, XP002188301
    - HUE, S. et al., "Interleukin-23 drives innate and T cell-mediated intestinal inflammation", Exp. Med., (20060000), vol. 203, doi:10.1084/jem.20061099, pages 2473 - 2483, XP055111922

DOI:   http://dx.doi.org/10.1084/jem.20061099
    - CUA, D.J. et al., "lnterleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain", Nature, (20030000), vol. 421, doi:10.1038/nature01355, pages 744 - 748, XP002971969

DOI:   http://dx.doi.org/10.1038/nature01355
    - MURPHY, C.A. et al., "Divergent pro- and anti-inflammatory roles for IL-23 and IL- 12 in joint autoimmune inflammation", J. Exp. Med., (20030000), vol. 198, pages 1951 - 1957
    - LEE, E. et al., "Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris", J. Exp. Med., (20040000), vol. 199, pages 125 - 130
    - TZANOS, J.S. et al., "Interleukin-1 7 production in central nervous system infiltrating T cells and glial cells is associated with active disease in multiple sclerosis", Am..I. Pathol., (20080000), vol. 172, pages 146 - 155
    - HUANG, X. et al., "Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients", Mod. Rheumatol., (20070000), vol. 17, pages 220 - 223, XP019495284
    - TUCCI, M. et al., "Overexpression of interieukin-12 and T helper 1 predominance in lupus nephritis", Clin Exp. Immunol, (20080000), vol. 154, pages 247 - 254
    - LEES, C.W. et al., "New IBD genetics: common pathways with other diseases", Gul, (20110000), vol. 60, pages 1739 - 1753
    - TAO, J.H. et al., "Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases", Mol. Biol. Rep., (20110000), vol. 38, doi:10.1007/s11033-010-0601-5, pages 4663 - 4672, XP019945210

DOI:   http://dx.doi.org/10.1007/s11033-010-0601-5
    - CHO, J.H. et al., "Recent insights into the genetics of inflammatory bowel disease", Gastroenterology, (20110000), vol. 140, pages 1704 - 1712
    - LEONARDI, C.L. et al., "PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)", Lancet, (20080000), vol. 371, pages 1665 - 1 674
    - SANDBOM, W.J. et al., "Ustekintunab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease", Gastroenterology, (20080000), vol. 135, pages 1130 - 1141
    - GOTTLIEB, A. et al., "Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial", Lancet, (20090000), vol. 373, pages 633 - 640
    - HALL, J.C. et al., "Type I interferons: crucial participants in disease amplification in autoimmunity", Nat. Rev. Rheumatol., (20100000), vol. 6, doi:10.1038/nrrheum.2009.237, pages 40 - 49, XP055541331

DOI:   http://dx.doi.org/10.1038/nrrheum.2009.237
    - BENNETT, L. et al., "Interferon and granulopoiesis signatures in systemic lupus eryt ematosus blood", J. Exp.Med, (20030000), vol. 197, pages 711 - 723
    - PETERSON, K.S, "Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli", J. Clin. Invest., (20040000), vol. 11, no. 3, pages 1722 - 1733
    - BENGTSSON, A.A. et al., "Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies", Lupus, (20000000), vol. 9, pages 664 - 671
    - SANTIAGO-RABER, M.L. et al., "Type-} interferon receptor deficiency reduces lupus-like disease in NZB mice", Exp. Med., (20030000), vol. 197, pages 777 - 788
    - DENG, Y. et al., "Genetic susceptibility to systemic lupus erythematosus in the genomic era", Nat. Rev. Rheumatol., (20100000), vol. 6, pages 683 - 692
    - SANDLING, J.K. et al., "A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE", Eur. J. Hum. Genet., (20110000), vol. 19, pages 479 - 484
    - BAVE, U. et al., "Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism", Arthritis Rheum., (20050000), vol. 52, pages 1185 - 1195
    - KIM. D. et al., "Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis", Arthritis Rheum., (20080000), vol. 58, pages 2163 - 2173
    - ISHIZAKI, M. et al., "Involvement of Tyrosine Kinase-2 in Both the IL-12/Thl and IL-23/Th17 Axes In vivo", J. Immunol., (20110000), vol. 187, pages 181 - 189
    - PRCHAL-MURPHY, M. et al., "TYK2 kinase activity is required for functional type I interferon responses in vivo", PLoS One, (20120000), vol. 7, page e39141
    - MINEGISHI, Y. et al., "Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity", Immunity, (20060000), vol. 25, doi:10.1016/j.immuni.2006.09.009, pages 745 - 755, XP055573304

DOI:   http://dx.doi.org/10.1016/j.immuni.2006.09.009
    - OYAMADA, A. et al., "Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis", Immunol., (20090000), vol. 183, pages 7539 - 7546
    - COUTURIER, N. et al., "Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility", Brain, (20110000), vol. 134, pages 693 - 703
    - ELLINGHAUS, D. et al., "Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci", Am. J. Hum. Genet., (20120000), vol. 90, pages 636 - 647
    - GRAHAM, D., "Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families", Rheumatology (Oxford), (20070000), vol. 46, pages 927 - 930
    - EYRE, S. et al., "High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis", Nat. Genet., (20120000), vol. 44, pages 1336 - 1340
    - RAUTIO, J., Nature Review Drug Discovery, (20180000), vol. 17, pages 559 - 587
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.